Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 18;16(24):4224.
doi: 10.3390/cancers16244224.

The Intersection of Psoriasis and Neoplasia: Risk Factors, Therapeutic Approaches, and Management Strategies

Larisa-Alexandra Mateescu  1 , Alexandra-Petruța Savu  1   2 , Costina-Cristiana Mutu  1 , Cezara-Diana Vaida  1 , Elena-Daniela Șerban  1   2 , Ștefana Bucur  1   2 , Elena Poenaru  2 , Alin-Codruț Nicolescu  2   3 , Maria-Magdalena Constantin  1   2
Affiliations
Review

The Intersection of Psoriasis and Neoplasia: Risk Factors, Therapeutic Approaches, and Management Strategies

Larisa-Alexandra Mateescu et al. Cancers (Basel). .

Abstract

The association between psoriasis and increased cancer risk is gaining recognition as studies reveal shared inflammatory and immune pathways. This review examines the relationship between psoriasis and neoplasia, focusing on cancer risk factors in psoriasis patients, the biological pathways underlying this connection, and the impact of various psoriasis treatments on cancer development. Psoriasis patients have a heightened incidence of certain cancers, such as lymphomas, skin cancers, and urological malignancies, potentially linked to immune dysregulation and chronic inflammation. Immunomodulatory treatments for psoriasis, including conventional systemic therapies and biologics, present varied cancer risks, with others, such as phototherapy, associated with an elevated risk of skin cancers. For oncologic patients with psoriasis, management necessitates a tailored approach, balancing effective psoriasis control with minimizing cancer progression risks. The emergence of IL-17 inhibitors, IL-23 inhibitors, and small-molecule therapies offers promising therapeutic alternatives with favorable safety profiles for these patients. This review underscores the need for interdisciplinary collaboration to optimize care for patients managing both psoriasis and malignancy.

Keywords: cancer; neoplasia; psoriasis; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Sewerin P., Brinks R., Schneider M., Haase I., Vordenbäumen S. Prevalence and incidence of psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 2019;78:286–287. doi: 10.1136/annrheumdis-2018-214065. - DOI - PubMed
    1. Parisi R., Symmons D.P., Griffiths C.E., Ashcroft D.M., Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) Project Team Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol. 2013;133:377–385. doi: 10.1038/jid.2012.339. - DOI - PubMed
    1. Kimball A.B., Gladman D., Gelfand J., Gordon K., Horn E.J., Korman N.J., Korver G., Krueger G.G., Strober B.E., Lebwohl M.G. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J. Am. Acad. Dermatol. 2008;58:1031–1042. doi: 10.1016/j.jaad.2008.01.006. - DOI - PMC - PubMed
    1. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009;361:496–509. doi: 10.1056/NEJMra0804595. - DOI - PubMed
    1. Constantin M.M., Ciurduc M.D., Bucur S., Olteanu R., Ionescu R.A., Constantin T., Furtunescu F. Psoriasis beyond the skin: Ophthalmological changes (Review) Exp. Ther. Med. 2021;22:981. doi: 10.3892/etm.2021.10413. - DOI - PMC - PubMed

LinkOut - more resources